Am­gen rolls out da­ta for KRAS in­hibitor com­bo study in col­orec­tal can­cer, hop­ing to move on from ug­ly ear­ly re­sults

With the first win for its KRAS in­hibitor so­tora­sib in hand, Am­gen is push­ing ahead with an ag­gres­sive clin­i­cal plan to cap­i­tal­ize on its first-to-mar­ket stand­ing. The drug­mak­er thinks com­bi­na­tions — in-house or oth­er­wise — could of­fer a path for­ward, and one ear­ly read­out from that strat­e­gy is bear­ing fruit.

A com­bi­na­tion of Am­gen’s so­tora­sib and its EGFR in­hibitor Vectibix post­ed an over­all re­sponse rate of 27% in 26 pa­tients with ad­vanced col­orec­tal can­cer (CRC) with the KRAS-G12C mu­ta­tion, ac­cord­ing to da­ta from the larg­er Phase Ib/II CODE­BREAK 101 study set to present at this week­end’s vir­tu­al ES­MO Con­gress.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER